Neutrophil‐Driven Cascade‐Targeted Nanocarriers Restore Mitochondrial Homeostasis to Ameliorate Renal Ischemia–Reperfusion Injury
Advanced Science · 2026-05 · 13 (30)
DOI: 10.1002/advs.202520940 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 30.03.2026. Verfasst von Hangbin Ma und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Center for Reproductive Medicine, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, …. Hauptthemen laut MEDLINE: Reperfusion Injury, Mitochondria, Neutrophils, Acute Kidney Injury. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Renal ischemia‐reperfusion injury (IRI) is a major cause of acute kidney injury (AKI), with high mortality and a significant risk of progression to chronic kidney disease (CKD). To address the lack of targeted therapies, we developed NKN‐LNP, a cascade‐targeting drug delivery system that enables spatiotemporally controlled delivery to injured tubules. This system first targets neutrophils via a surface polypeptide, hijacking their inflammatory migration to traverse the glomerular barrier and reach the injury site. Microenvironmental matrix metalloproteinase 2/9 (MMP‐2/9) then triggers nanoparticle release, exposing a second peptide that selectively binds to upregulated kidney injury molecule‐1 (KIM1) on tubular cells. Loaded with the NAD + precursor β‐nicotinamide mononucleotide (NMN), the accumulated NKN‐LNP potently activates the NAD + ‐SIRT3 signaling axis, restoring mitochondrial function and ameliorating renal damage in AKI mice. Importantly, this targeted strategy also exerts potent antifibrotic effects, thereby mitigating the AKI‐to‐CKD transition. This neutrophil‐mediated dual‐targeting platform offers a promising nanotherapeutic strategy for precise treatment of renal IRI and its chronic progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Center for Reproductive Medicine, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
- Department of Pharmacy, Center for Regenerative and Aging Medicine, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University,…
ORCID-Profile: Longguang Tang
Förderung
- National Natural Science Foundation of China
- Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China
Zitieren
APA
Ma, H., Li, Y., Lin, S., Chu, F., Ren, G., Mao, Y., Wu, M., Ma, Y., Ji, Q., Chen, Z., Ji, J., Sun, M., Xu, Y., Sun, X., Tang, L., & Zhou, H. (2026). Neutrophil‐Driven Cascade‐Targeted Nanocarriers Restore Mitochondrial Homeostasis to Ameliorate Renal Ischemia–Reperfusion Injury. Advanced Science, 13(30). https://doi.org/10.1002/advs.202520940
Vancouver
Ma H, Li Y, Lin S, Chu F, Ren G, Mao Y, et al. Neutrophil‐Driven Cascade‐Targeted Nanocarriers Restore Mitochondrial Homeostasis to Ameliorate Renal Ischemia–Reperfusion Injury. Advanced Science. 2026;13(30). doi:10.1002/advs.202520940
BibTeX
@article{Ma2026,
author = {Ma, Hangbin and Li, Yang and Lin, Shen and Chu, Feifan and Ren, Gaozhan and Mao, Yinhui and Wu, Mingzhi and Ma, Yuning and Ji, Qiwei and Chen, Zujie and Ji, Jinzhong and Sun, Mingxin and Xu, Yongpeng and Sun, Xiaoli and Tang, Longguang and Zhou, Hao},
title = {Neutrophil‐Driven Cascade‐Targeted Nanocarriers Restore Mitochondrial Homeostasis to Ameliorate Renal Ischemia–Reperfusion Injury},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {30},
doi = {10.1002/advs.202520940}
}
EUVIMED